Table 1 Patient characteristics in the 1st line endocrine setting (n = 16)
From: Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
Variable | n (%), median (range) |
|---|---|
Median age at AI initiation | 55 years (39–72) |
Performance status | |
0 | 4 (25%) |
1 | 10 (62.5%) |
2 | 1 (6.25%) |
3 | 1 (6.25%) |
Menopausal status | |
Premenopausal | 2 (12.5%) |
Postmenopausal | 14 (87.5%) |
Median body mass index | 27.6 kg/m2 (20.3–52.7) |
Number of co-morbidities | |
0–1 | 13 (81%) |
2–3 | 3 (19%) |
4–5 | 0 (0%) |
Stage at diagnosis | |
Non metastatic | 11 (69%) |
Locally recurrent/ metastatic | 5 (31%) |
Sites of metastases at time of AI initiation | |
Lung | 12 (75%) |
[Lung as only site of metastases] | 10 (62.5%) |
Pelvis | 4 (25%) |
Peritoneum | 3 (19%) |
Tumour volume at time of AI initiation | |
Low | 6 (37.5%) |
High | 10 (62.5%) |
Number of metastases | |
Oligometastatic | 7 (44%) |
Multiple | 9 (56%) |